

Je-Hwan Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5774540/publications.pdf>

Version: 2024-02-01

187
papers

3,814
citations

172207

29
h-index

155451

55
g-index

191
all docs

191
docs citations

191
times ranked

5080
citing authors

#	ARTICLE	IF	CITATIONS
1	Unique ethnic features of <i>DDX41</i> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 510-518.	1.7	33
2	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 179-189.	0.7	2
3	Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. <i>European Journal of Haematology</i> , 2022, 109, 58-68.	1.1	5
4	Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning-Based Model Development and Validation. <i>JMIR Medical Informatics</i> , 2022, 10, e32313.	1.3	3
5	Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2022, 198, 703-712.	1.2	6
6	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
7	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.4	29
8	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	0.8	2
9	Incidence, Management, and Prognosis of Graft Failure and Autologous Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2021, 36, e151.	1.1	5
10	Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14199.	0.8	4
11	Clinical features and outcomes of hypocellular acute myeloid leukemia in adults. <i>Medicine (United States)</i> , 2021, 100, e25448.	0.4	4
12	Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial. <i>International Journal of Hematology</i> , 2021, 113, 851-860.	0.7	6
13	Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome. <i>Leukemia Research</i> , 2021, 103, 106540.	0.4	1
14	Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis. <i>Medicine (United States)</i> , 2021, 100, e25448.	0.4	4
15	Diagnostic yield of a bronchoalveolar lavage fluid galactomannan assay in patients with negative serum galactomannan results suspected to have invasive pulmonary aspergillosis. <i>Mycoses</i> , 2021, 64, 1124-1131.	1.8	2
16	Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry. <i>PLoS ONE</i> , 2021, 16, e0251011.	1.1	4
17	Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. <i>Blood Research</i> , 2021, 56, 102-108.	0.5	0
18	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	1.2	10
20	Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia. <i>Annals of Laboratory Medicine</i> , 2021, 41, 479-484.	1.2	1
21	A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3425-3425.	0.6	0
22	Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3683-3683.	0.6	0
23	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. <i>Blood</i> , 2021, 138, 700-700.	0.6	18
24	A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2021, 36, e306.	1.1	13
25	Diagnostic usefulness of differential time to positivity in neutropenic cancer patients with suspected catheter-related candidemia. <i>Medical Mycology</i> , 2020, 58, 137-140.	0.3	2
26	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	1.0	1
27	Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2020, 105, 262-273.	1.1	3
28	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 2032-2043.	2.5	38
29	Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2223-2232.	2.0	10
30	Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy. <i>Annals of Hematology</i> , 2020, 99, 1231-1239.	0.8	0
31	Treatment of Latent Tuberculosis Infection Based on the Interferon- γ Release Assay in Allogeneic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 1977-1979.	2.9	9
32	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468.	1.3	2
33	Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 429-437.	0.7	3
34	Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study. <i>British Journal of Haematology</i> , 2019, 187, e4-e7.	1.2	5
35	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 656-664.	0.2	5
36	Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study. <i>In Vivo</i> , 2019, 33, 2273-2280.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
38	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, e151-e155.	1.2	2
39	Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma. <i>Annals of Laboratory Medicine</i> , 2019, 39, 496-498.	1.2	2
40	Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). <i>Bone Marrow Transplantation</i> , 2019, 54, 1361-1368.	1.3	20
41	Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 290-299.e3.	0.2	6
42	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. <i>Annals of Hematology</i> , 2019, 98, 1135-1147.	0.8	9
43	Fludarabine/Melphalan 100 mg/m ² Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1116-1121.	2.0	8
44	DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3002-3002.	0.6	3
45	Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 390-400.	0.7	14
46	Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R. <i>Blood</i> , 2019, 134, 3009-3009.	0.6	0
47	Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy. <i>Medical Mycology</i> , 2018, 56, 782-786.	0.3	8
48	Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 68, 51-56.	0.4	22
49	Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors. <i>Leukemia and Lymphoma</i> , 2018, 59, 1829-1839.	0.6	0
50	Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. <i>Blood Research</i> , 2018, 53, 288.	0.5	4
51	The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data. <i>Immune Network</i> , 2018, 18, e2.	1.6	4
52	TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 74, 97-104.	0.4	9
53	Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes. <i>Acta Haematologica</i> , 2018, 139, 220-227.	0.7	4
54	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	0.6	44

#	ARTICLE	IF	CITATIONS
55	Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. <i>Annals of Hematology</i> , 2017, 96, 605-615.	0.8	5
56	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1555-1566.	2.0	21
57	Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients. <i>Journal of Clinical Virology</i> , 2017, 87, 5-11.	1.6	10
58	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <i>Leukemia Research</i> , 2017, 60, 135-144.	0.4	8
59	Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of the RISK Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1773-1779.	2.0	29
60	Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow. <i>Experimental Hematology</i> , 2017, 45, 56-63.	0.2	22
61	Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5. <i>Oncotarget</i> , 2017, 8, 11748-11762.	0.8	14
62	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	0.5	11
63	Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 2754-2763.	0.8	65
64	Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. <i>Oncotarget</i> , 2017, 8, 41387-41400.	0.8	9
65	Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 245.	0.6	1
66	Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 63.	0.6	20
67	A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea. <i>Annals of Laboratory Medicine</i> , 2016, 36, 79-81.	1.2	9
68	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214.	1.1	51
69	Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. <i>PLoS ONE</i> , 2016, 11, e0167641.	1.1	27
70	A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 years with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. <i>European Journal of Haematology</i> , 2016, 96, 188-197.	1.1	11
71	Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients. <i>Transplant International</i> , 2016, 29, 549-558.	0.8	34
72	Recurrent pulmonary embolism during dabigatran treatment in a patient with immune thrombocytopenic purpura. <i>Thrombosis Research</i> , 2016, 148, 23-24.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study. <i>Annals of Hematology</i> , 2016, 95, 1223-1232.	0.8	14
74	Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen–Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2065-2076.	2.0	31
75	Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia. <i>Acta Haematologica</i> , 2016, 136, 129-139.	0.7	9
76	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 159-166.	0.7	1
77	Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%—a feasibility study. <i>Annals of Hematology</i> , 2016, 95, 1151-1161.	0.8	4
78	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	1.7	68
79	Restrictive chronic lung function decline after haematopoietic stem cell transplantation. <i>European Respiratory Journal</i> , 2016, 47, 336-339.	3.1	4
80	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133.	0.8	14
81	Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2016, 7, 55264-55275.	0.8	62
82	Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 961-970.	0.7	19
83	Extracorporeal Membrane Oxygenation Support in Adult Patients with Hematologic Malignancies and Severe Acute Respiratory Failure. <i>Korean Journal of Critical Care Medicine</i> , 2016, 31, 243-250.	0.1	4
84	Retrospective Case Series Study of Hypomethylating Therapy in IPSS Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1992-1992.	0.6	1
85	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	0.6	160
86	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	2.0	37
87	Prognostic role of FEV ₁ for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2015, 29, 1133-1139.	0.8	21
88	JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. <i>Journal of Korean Medical Science</i> , 2015, 30, 882.	1.1	16
89	Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation. <i>Blood Research</i> , 2015, 50, 123.	0.5	4
90	Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression. <i>Blood Research</i> , 2015, 50, 227.	0.5	12

#	ARTICLE	IF	CITATIONS
91	Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0119379.	1.1	24
92	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. <i>Lancet Haematology</i> , 2015, 2, e417-e426.	2.2	64
93	Feasible Outcomes of T Cell-Depleted Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 342-349.	2.0	23
94	Monosomal karyotype in acute myeloid leukemia and the role of allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 795-801.	0.8	4
95	Up-Front Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Arising from the Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2015, 133, 183-192.	0.7	3
96	Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2015, 134, 40-48.	0.7	12
97	Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2015, 94, 546-553.	1.1	11
98	A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 655-663.	0.2	4
99	A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2535-2535.	0.6	1
100	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015, 126, 2861-2861.	0.6	7
101	Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>Journal of Clinical Oncology</i> , 2015, 33, 7044-7044.	0.8	22
102	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 44985-44994.	0.8	17
103	Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. <i>Blood</i> , 2015, 126, 4789-4789.	0.6	0
104	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61.	1.1	4
105	A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2014, 69, 165-173.	1.7	38
106	Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2014, 99, 635-643.	0.7	16
107	Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen-Depleted Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 696-704.	2.0	118
108	Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome. <i>Korean Journal of Medicine</i> , 2014, 87, 496.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 5151-5151.	0.6	0
110	Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3654-3654.	0.6	0
111	A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis. <i>Blood</i> , 2014, 124, 3890-3890.	0.6	0
112	Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 1101-1110.	0.8	5
113	Prognostic implications of CD14 positivity in acute myeloid leukemia arising from myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2013, 97, 246-255.	0.7	7
114	Fludarabine, cytarabine, and attenuated-dose idarubicin (FLAI) combination therapy for elderly acute myeloid leukemia patients. <i>American Journal of Hematology</i> , 2013, 88, 10-15.	2.0	14
115	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757.	0.7	98
116	Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. <i>Annals of Hematology</i> , 2013, 92, 889-897.	0.8	27
117	Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine. <i>Journal of Clinical Oncology</i> , 2013, 31, 701-709.	0.8	99
118	Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. <i>Blood Research</i> , 2013, 48, 87.	0.5	13
119	Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. <i>Blood Research</i> , 2013, 48, 178.	0.5	26
120	Efficacy Of Helicobacter Pylori Eradication For The First Line Treatment Of Immune Thrombocytopenia Patients With Moderate Thrombocytopenia. <i>Blood</i> , 2013, 122, 2324-2324.	0.6	0
121	Comparable Allogeneic Hematopoietic Cell Transplantation Outcome Of Haplo-Identical Family Donor With Matched Unrelated/Mismatched Family Donor In Adult Aplastic Anemia. <i>Blood</i> , 2013, 122, 1230-1230.	0.6	0
122	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	0.6	1
123	Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2012, 127, 63-71.	0.7	19
124	A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. <i>Annals of Hematology</i> , 2012, 91, 1459-1469.	0.8	25
125	Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 671-677.	0.8	17
126	Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1222-1230.	2.0	55

#	ARTICLE	IF	CITATIONS
127	A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 1441-1447.	1.7	58
128	Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. <i>Blood</i> , 2011, 118, 2609-2617.	0.6	94
129	A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. <i>Blood</i> , 2011, 118, 3832-3841.	0.6	136
130	Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia. <i>European Journal of Haematology</i> , 2011, 87, 172-181.	1.1	9
131	A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy. <i>Annals of Hematology</i> , 2011, 90, 1283-1291.	0.8	4
132	Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated donors. <i>American Journal of Hematology</i> , 2011, 86, 399-405.	2.0	10
133	Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2011, 35, 152-158.	0.4	40
134	Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. <i>Leukemia Research</i> , 2011, 35, 499-503.	0.4	31
135	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. <i>Blood</i> , 2011, 118, 1517-1517.	0.6	6
136	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 3166-3166.	0.6	7
137	Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2011, 118, 2031-2031.	0.6	0
138	Retrospective Comparison of Azacitidine and Decitabine in the Treatment of Myelodysplastic Syndrome. <i>Blood</i> , 2011, 118, 3809-3809.	0.6	0
139	Validation of New Prognostic Model Including Comorbidities in Patients with Myelodysplastic Syndrome Receiving Hypomethylating Therapy. <i>Blood</i> , 2011, 118, 1708-1708.	0.6	0
140	Prognostic Implications of CD14 Positivity in Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome. <i>Blood</i> , 2011, 118, 3523-3523.	0.6	1
141	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 5273-5273.	0.6	0
142	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. <i>Annals of Hematology</i> , 2010, 89, 15-23.	0.8	10
143	Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission. <i>The Korean Journal of Hematology</i> , 2010, 45, 95.	0.7	2
144	High Dose Dexamethasone Vs. Conventional Dose Prednisolone for Adults with Immune Thrombocytopenia: a Prospective Multicenter Phase III Trial. <i>Blood</i> , 2010, 116, 3687-3687.	0.6	29

#	ARTICLE	IF	CITATIONS
145	Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor After Reduced-Intensity Conditioning Containing Busulfan, Fludarabine, and Antithymocyte Globulin for Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2010, 116, 3538-3538.	0.6	0
146	Prospective Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition to Anti-Thymocyte Globulin for the Conditioning Therapy In Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome. <i>Blood</i> , 2010, 116, 34-34.	0.6	0
147	Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. <i>Blood</i> , 2010, 116, 3536-3536.	0.6	1
148	Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. <i>Leukemia Research</i> , 2009, 33, 426-433.	0.4	10
149	Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 511-517.	0.4	5
150	Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients.. <i>Blood</i> , 2009, 114, 2284-2284.	0.6	1
151	A Case Report of Rituximab Therapy for Recurrent Thrombotic Thrombocytopenia Purpura. <i>The Korean Journal of Hematology</i> , 2009, 44, 193.	0.7	0
152	Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation.. <i>Blood</i> , 2009, 114, 1179-1179.	0.6	0
153	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. <i>Blood</i> , 2009, 114, 4298-4298.	0.6	0
154	Genomic Copy Number Alterations and Clustering Analysis Using Array CGH in Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2009, 114, 1008-1008.	0.6	0
155	Two Cycles of PAD Combination (PS-341/Bortezomib, Adriamycin and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation (AHCT) in Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2009, 114, 2322-2322.	0.6	1
156	Rapid Detection of Nucleophosmin (NPM1) Mutations to Determine Prognostic Implications in Acute Myeloid Leukemia Patients with a Normal Karyotype.. <i>Blood</i> , 2009, 114, 4676-4676.	0.6	0
157	Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia: Role of the NPM1 Mutations May Be Different in Different Races.. <i>Blood</i> , 2009, 114, 4684-4684.	0.6	0
158	C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1601-1604.	0.4	32
159	Prognostic implications of the immunophenotype in biphenotypic acute leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 700-709.	0.6	44
160	The Molecular Screening Using Multiplex Reverse Transcription Polymerase Chain Reaction and the Comparison with Cytogenetic Analysis in the Prognostic Stratification of Acute Leukemia. <i>Blood</i> , 2008, 112, 4868-4868.	0.6	0
161	Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1095-1105.	2.0	62
162	Similar Background of Graft-Versus-Host Disease (GVHD) Following Allogeneic Blood and Marrow Transplantation (Tx) in Korean and Japanese Populations Allows a Uniform Foundation To Perform Large-Scale Clinical Studies in the Region.. <i>Blood</i> , 2007, 110, 5007-5007.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Preliminary Results of a Prospective Multicenter Phase III Trial Comparing High-Dose and Standard-Dose Daunorubicin for Induction of Complete Remission (CR) in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1833-1833.	0.6	0
164	Prevalence and Trend of Hematopoietic Stem Cell Transplantation for Adult Aplastic Anemia/Pure Red Cell Aplasia in Korea.. Blood, 2007, 110, 3757-3757.	0.6	0
165	Continuous Infusion of FLAG and Idarubicin for Patients Younger Than 60 Years with Resistant Acute Myeloid Leukemia; a Prospective, Multicenter Phase II Study.. Blood, 2007, 110, 4350-4350.	0.6	0
166	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. Blood, 2007, 110, 4615-4615.	0.6	0
167	HLA-Haploidentical Familial Donor Hematopoietic Cell Transplantation without Ex Vivo- T Cell Depletion after Reduced-Intensity Conditioning of Busulfan, Fludarabine, and Anti-Thymocyte Globulin: A Preliminary Report.. Blood, 2007, 110, 3077-3077.	0.6	0
168	Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leukemia Research, 2006, 30, 204-210.	0.4	13
169	Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. Annals of Hematology, 2006, 85, 357-365.	0.8	6
170	Hypoplastic Acute Myeloid Leukemia.. Blood, 2006, 108, 4493-4493.	0.6	1
171	Prognostic Implications of the Immunophenotype in Biphenotypic Acute Leukemia.. Blood, 2006, 108, 2319-2319.	0.6	0
172	Prognostic Significance of FLT3 Mutations in Paired Initial and Relapse Marrow Samples of Acute Myeloid Leukemia Excluding Acute Promyelocytic Leukemia.. Blood, 2006, 108, 4440-4440.	0.6	0
173	Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Annals of Hematology, 2005, 84, 321-330.	0.8	84
174	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. Blood, 2005, 106, 5415-5415.	0.6	0
175	Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5337-5337.	0.6	0
176	Time to First Acute Exacerbation Can Stratify the Patients According to Their Prognosis during Clinical Course of Chronic GVHD: Evaluation of New End-Point for Chronic GVHD.. Blood, 2005, 106, 5335-5335.	0.6	0
177	Standard Induction Followed by Attenuated Consolidation Therapy in Elderly Patients with Acute Myeloid Leukemia.. Blood, 2005, 106, 4602-4602.	0.6	0
178	Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica, 2005, 90, 285-6.	1.7	23
179	Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica, 2005, 90, 1380-8.	1.7	45
180	Prognostic Factors Identifiable at the Time of Onset of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.. Blood, 2004, 104, 1247-1247.	0.6	0

#	ARTICLE	IF	CITATIONS
181	A Risk Model for Early Intracranial Hemorrhage in Acute Leukemia.. Blood, 2004, 104, 4473-4473.	0.6	0
182	Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. British Journal of Haematology, 2003, 120, 702-710.	1.2	48
183	Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2003, 122, 637-644.	1.2	21
184	Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. British Journal of Haematology, 2002, 118, 1087-1094.	1.2	56
185	Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. Leukemia Research, 2001, 25, 213-216.	0.4	12
186	Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leukemia Research, 2001, 25, 305-312.	0.4	29
187	Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer, 1995, 75, 2794-2801.	2.0	65